<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-14 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-14</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-14</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-164502a687f04effb4ac5dadbdd9d806fde4264c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/164502a687f04effb4ac5dadbdd9d806fde4264c" target="_blank">Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> This study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers and indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e14.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e14.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR (overall)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal Growth Factor Receptor (kinase domain) mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent activating mutations in the EGFR kinase domain (exon 18-21), including exon 19 deletions and L858R, are the dominant driver alterations in this cohort of East Asian never-smoker lung adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR kinase domain mutations (exon 19 deletions, L858R, exon 20 insertion, G719S+L861Q double)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations; small in-frame deletions; insertion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>78.8% (41 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted PCR amplification and Sanger sequencing (mutational analysis) in tumor samples; mutual exclusivity analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Enriched in never-smokers and females in this cohort (82.9% of female tumors, 63.6% of male tumors); mostly exon 19 deletions and L858R</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Predicts sensitivity to EGFR TKIs (gefitinib, erlotinib); however exon 20 insertion associated with resistance; concurrent PIK3CA mutations may influence response</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR amplification and Sanger sequencing of EGFR exons 18-22 from cDNA/genomic DNA</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e14.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR exon 19 del</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exon 19 in-frame deletions (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>In-frame deletions in EGFR exon 19, a common activating alteration associated with sensitivity to EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR exon 19 deletion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame deletion (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>40.4% (21 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted sequencing (mutational analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Predominant EGFR mutation type in this cohort; more frequent in females</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Associated with sensitivity to EGFR TKIs (gefitinib/erlotinib)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing of EGFR exons 18-22</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e14.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR L858R</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR L858R (exon 21) point mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A recurrent activating point mutation in EGFR (L858R) that confers sensitivity to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR L858R (Leu858Arg)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>34.6% (18 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted PCR amplification and sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Common in never-smokers; enriched among female cases in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Predicts sensitivity to EGFR TKIs (gefitinib/erlotinib)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing of EGFR exons 18-22</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e14.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR exon 20 insertion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR exon 20 insertion (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A rare EGFR kinase domain insertion in exon 20 observed in one tumor; exon 20 insertions are associated with primary resistance to first-generation EGFR TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR exon 20 insertion</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>insertion (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1.9% (1 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted sequencing; literature-cited association with drug resistance</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Cited association with resistance to EGFR TKIs (from literature), but no functional assays reported in this study</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Present in a small minority; may confer primary resistance to EGFR inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Associated with reduced sensitivity to gefitinib/erlotinib</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e14.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR G719S+L861Q</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR G719S (exon 18) and L861Q (exon 21) double mutation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A double EGFR mutation involving G719S and L861Q observed in one tumor (co-occurring point mutations in different exons of EGFR).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR G719S + L861Q (double point mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations (missense, double)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1.9% (1 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted sequencing (mutational analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Likely relevant to EGFR-targeted therapy decisions (not directly tested in this study)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing of EGFR exons</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e14.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EML4-ALK</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EML4-ALK fusion gene (multiple variants)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Oncogenic ALK fusions with EML4 were detected in a subset of tumors, with multiple fusion variants (E13;A20, E20;A20, E6a/b;A20) reported.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EML4-ALK gene fusion (variants E13;A20, E20;A20, E6a/b;A20)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (oncogenic fusion creating ALK kinase activation)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK fusion / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>5.8% (3 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>27.3% (3 of 11 EGFR-wild-type tumors; reported as 28% of EGFR wild-type)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>RT-PCR (cDNA) multiplex amplification for known fusion variants and Sanger sequencing confirmation</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found among EGFR-wild-type tumors; mutually exclusive with EGFR/HER2/KRAS alterations</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ALK inhibitors (e.g., crizotinib) have demonstrated clinical efficacy against ALK fusion-positive lung cancers (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Multiplex PCR of cDNA using primers covering known EML4-ALK variants and sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e14.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HER2 (ERBB2) insertions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>HER2 (ERBB2) kinase domain insertions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Small insertions in the HER2 kinase domain were detected in two tumors; HER2 kinase mutations are an actionable RTK alteration in a minority of lung adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>HER2 kinase domain insertions</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame insertion (kinase domain)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>HER2 (ERBB2) / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3.8% (2 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>cDNA PCR amplification and sequencing of HER2 exons 18-21</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected in never-smoker cohort; mutually exclusive with other known drivers</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>HER2-targeted inhibitors (EGFR/HER2 inhibitor BIBW2992 referenced with clinical activity in HER2-mutant lung tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing of HER2 exons 18-21</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e14.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS G12V</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS G12V (glycine 12 to valine)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An activating KRAS codon 12 mutation (G12V) was detected in one tumor, representing a rare occurrence in never-smokers within this East Asian cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS G12V</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS / RAS</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>1.9% (1 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>9.1% (1 of 11 EGFR-wild-type tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>cDNA PCR amplification and sequencing of KRAS exons 2-3</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Rare in never-smokers and in East Asian populations in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>No targeted therapy described in this paper; KRAS mutations are generally associated with lack of EGFR TKI sensitivity</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing of KRAS exons 2-3</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e14.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF (no mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF kinase mutations (negative in this cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>No BRAF mutations were detected in the 52 tumors analyzed.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>No BRAF mutations detected</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (assessed but none found)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF / RAF-MAPK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% (0 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>0% (0 of 5 pan-wild-type tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted sequencing of BRAF exons 11-15 (mutational analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>BRAF mutations not observed in this never-smoker East Asian cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>cDNA PCR and sequencing of BRAF exons 11-15</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e14.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PIK3CA (PI3K catalytic subunit alpha) mutations: E545K and H1047R</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PIK3CA hotspot mutations (E545K in exon 9 and H1047R in exon 20) were found in four tumors, and in all cases these co-occurred with EGFR mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PIK3CA E545K (exon 9) and H1047R (exon 20)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (hotspot missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PIK3CA / PI3K-AKT pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>7.7% (4 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>0% in pan-wild-type tumors (all PIK3CA mutations co-occurred with EGFR mutations; none in the 5 driver-negative tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted sequencing of PIK3CA exons 9 and 20; co-occurrence analysis with EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Literature-cited in vitro association with resistance to EGFR TKIs; no new functional assays in this study</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>More commonly found in younger patients in this small series; always co-occurred with EGFR mutations here</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>May modulate response to EGFR TKIs (potential resistance mechanism); suggests combinatorial targeting could be relevant</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genomic DNA sequencing of PIK3CA exons 9 and 20</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e14.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>TP53 tumor suppressor gene mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mutations in TP53 were detected in 15 tumors (tumor suppressor alterations), representing a common co-occurring event in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TP53 mutations (various, exonic sequencing performed)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutations / loss-of-function (tumor suppressor gene)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TP53 / genome integrity pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>28.8% (15 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic DNA sequencing of all TP53 exons (mutational analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Mutation rate similar to previous studies in comparable populations</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genomic DNA PCR and sequencing of all TP53 exons</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e14.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>LKB1 (STK11) (no mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>LKB1 (STK11) tumor suppressor gene (assessed, none detected)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>No mutations in the tumor suppressor LKB1 (STK11) were detected in this cohort; LKB1 mutations are reported to be less frequent in Asian lung cancer patients.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>No LKB1 mutations detected</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (assessed but none found)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>LKB1 (STK11) / tumor suppressor</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% (0 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>0% (0 of 5 pan-wild-type tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic DNA sequencing of all LKB1 exons</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Consistent with prior reports of lower LKB1 mutation frequency in Asian patients</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Genomic DNA sequencing of LKB1 full coding region</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e14.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HRAS/NRAS (no mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>HRAS and NRAS (RAS family) (assessed, none detected)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>No mutations were detected in HRAS or NRAS in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>No HRAS or NRAS mutations detected</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (assessed but none found)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>HRAS, NRAS / RAS</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>0% (0 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td>0% (0 of 5 pan-wild-type tumors)</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>targeted sequencing of HRAS and NRAS (exons assessed)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>PCR and sequencing of RAS gene exons</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e14.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pan-wild-type tumors</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumors lacking detectable EGFR/HER2/KRAS/BRAF/EML4-ALK alterations (driver-negative / pan-wild-type)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A minority of tumors (5 of 52) did not harbor any of the major tested driver alterations; the authors highlight these as subjects for further genomic investigation to find alternative drivers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>Pan-wild-type status (no EGFR, HER2, KRAS, BRAF, or EML4-ALK detected)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>absence of tested driver mutations (driver-negative)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>9.6% (5 of 52)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>negative results from targeted mutational testing (sequencing and fusion PCR) and array analyses reported as preliminary</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>All five pan-wild-type cases were from female patients in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>These tumors may harbor other alterations (non-EML4 ALK fusions, ROS fusions, PDGFR amplification, etc.) and could require broader genomic profiling for targeted therapy assignment</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Comprehensive targeted sequencing for EGFR/HER2/KRAS/BRAF/PIK3CA/TP53/LKB1/HRAS/NRAS and RT-PCR for EML4-ALK; exon array and SNP array data queried (preliminary)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e14.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KIF5B-ALK (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KIF5B-ALK fusion (candidate ALK fusion alternative to EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Mentioned as a recently described non-EML4 ALK fusion that could account for ALK-driven tumors not detected by EML4-ALK PCR assays; authors report no evidence for non-EML4 ALK fusions in their pan-wild-type cases but list KIF5B-ALK as a plausible alternate driver.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KIF5B-ALK gene fusion (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK fusion / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature-cited candidate (not detected in this study's pan-wild-type samples)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Would be targetable by ALK inhibitors if present; authors checked exon-array expression and found no evidence in these samples</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Mentioned as a possible fusion; authors attempted exon-array and did not find supporting evidence in pan-wild-type tumors</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e14.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS fusions (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 gene fusions (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ROS1 fusion events are mentioned as alternative driver candidates for tumors lacking canonical drivers; preliminary exon-array and SNP-array analyses did not find evidence for ROS fusions in the pan-wild-type tumors in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1 fusions (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature-cited candidate; authors report no preliminary evidence in their exon-array/SNP-array data</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>If present, ROS1 fusions have targeted therapeutic implications (ROS1 inhibitors), but not detected here</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Discussed as a candidate; preliminary exon-array and SNP-array did not support presence in pan-wild-type samples</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e14.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PDGFR amplification (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PDGFR (PDGFRA) amplification (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>PDGFR amplification is mentioned as a possible alternative genomic event that could drive some tumors lacking canonical driver mutations; authors' preliminary analyses did not find evidence for this event in their samples.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PDGFR (PDGFRA) amplification (candidate)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene amplification / copy number alteration</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PDGFRA / RTK</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature-cited candidate; preliminary exon-array and SNP-array analysis did not find evidence in this cohort</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>If present, amplification could suggest sensitivity to PDGFR-targeted therapies; not observed in this study</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Mentioned as candidate; authors searched exon-array and SNP-array data without positive findings</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK <em>(Rating: 2)</em></li>
                <li>Somatic mutations affect key pathways in lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>PIK3CA mutations and copy number gains in human lung cancers <em>(Rating: 2)</em></li>
                <li>KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>